Decentralized exchanges (DEXs) have nearly doubled their share of spot trading from 6.9% in January 2024 to 13.6% in January 2026, with perpetual futures DEX share rising from 2.0% to 10.2% in the same period. This growth is attributed to lower operating costs in custody, security, and customer verification, as well as improved trading interfaces. However, centralized exchanges still dominate overall trading volume and are preferred by Ethena Labs for hedging its synthetic dollar due to their risk controls. The rise in DEX trading share shows a shift in market dynamics but is not solely due to cost advantages.
The story on Ethena Founder and DEX market share is presented with Pluang's cryptocurrency market data for context. For readers following major cryptocurrencies, as of Oct 21, 2026 06:12 WIB, 45 of 50 major cryptocurrencies rose while 4 fell. BAL (Balancer) led gains with an 11.14% increase to Rp16.297 and a typical hold time of 85 days, compared to EOS (EOS.IO) at Rp12.649 with an 8.13% rise and 87 days hold time, and VET (VeChain) at Rp129 with a 6.11% increase, a longer hold time of 148 days, and a nearly balanced Pluang order activity of 49% Sell to 51% Buy.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
